In an illustration of how techniques for studying the proteome are finding an increasingly wide array of potential applications in drug discovery, AstraZeneca last week agreed to work with Ambit Biosciences to use the company’s phage display and affinity chromatography technology to identify proteins that interact with specific small molecules.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.